Neratinib has a synergistic antitumor effect with everolimus in PIK3CA-mutated HER2+ breast cancer patient-derived xenograft models and with trametinib in HER2-mutated HER2+ breast cancer patient-derived xenograft models [27]. Here, PIK3CA is linked to breast cancer.